Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100

NCT01605227 is registered in ClinicalTrials.gov with Exelixis as lead sponsor.

NCT NCT01605227
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01605227 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
Lead sponsor
Exelixis
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2012
Completion date
March 31, 2015
Enrollment
1,028 (actual)
Sites
264

Conditions

As the registry lists them; a condition with its own page is linked.

castration resistant prostate cancer, pain, prostate cancer, prostatic neoplasms